InsiderSignal.AI

InsiderSignal.ai

CABA - Cabaletta Bio, Inc.

Insider Purchase by Simon Mark (Dir)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

1 month ago, Simon Mark, serving as Dir at Cabaletta Bio, Inc. (CABA), purchased 11,061 shares at $2.28 per share, for a total transaction value of $25,261.00. Following this transaction, Simon Mark now holds 154,205 shares of CABA.

This purchase represents a 8.00% increase in Simon Mark's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, January 21, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, January 21, 2026, meaning the disclosure happened on the same day as the trade.

Cabaletta Bio, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Simon Mark

Dir

Mark Simon is a Class III independent director at Cabaletta Bio, Inc. (CABA), serving on the board since October 2018 and nominated for a term ending at the 2028 annual meeting.[[1]](https://fintool.com/app/research/companies/CABA/people/mark-simon)[[3]](https://www.cabalettabio.com/about/board-of-directors) He chairs the Compensation Committee and serves on the Audit and Nominating & Corporate Governance Committees, attending over 90% of board and committee meetings in 2024.[[1]](https://fintool.com/app/research/companies/CABA/people/mark-simon)[[6]](https://www.cabalettabio.com/investors/corporate-governance) Simon brings over 35 years of experience in life sciences investment banking and equity research, including as Managing Director and Head of Life Sciences Investment Banking at Citigroup (2002–2005) and at Robertson Stephens, where he oversaw biotech investment banking and helped raise 45% of U.S. biotech dollars in 1999–2001.[[1]](https://fintool.com/app/research/companies/CABA/people/mark-simon) He is a co-founder of Torreya Partners LLC (acquired by Stifel in 2023), Strategic Advisor to the Founder/CEO of Sun Pharmaceutical Industries Ltd. since 2020, and holds other roles such as Vice Chairman at Alliance for Aging Research and director at Hutchison Biofilm Medical Solutions.[[2]](https://www.marketscreener.com/insider/MARK-SIMON-A1EC6O/)[[3]](https://www.cabalettabio.com/about/board-of-directors) Simon holds an MBA from Harvard Business School and a BA from Columbia College.[[1]](https://fintool.com/app/research/companies/CABA/people/mark-simon)[[3]](https://www.cabalettabio.com/about/board-of-directors) On January 21, 2026, he purchased 11,061 shares of CABA for $25,261, owning 147,205 shares directly and 7,000 indirectly.[[4]](https://www.investing.com/news/insider-trading-news/simon-mark-cabaletta-bio-director-buys-25261-in-shares-93CH-4459141)

View full insider profile →

Trade Price

$2.28

Quantity

11,061

Total Value

$25,261.00

Shares Owned

154,205

Trade Date

Wednesday, January 21, 2026

32 days ago

SEC Filing Date

Wednesday, January 21, 2026

HEALTHCAREBIOTECHNOLOGY

About Cabaletta Bio, Inc.

Company Overview

No company information available
View news mentioning CABA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3307002

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime